Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.86 USD | +4.64% | +9.38% | +24.32% |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
05-07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.32% | 5.58B | |
+7.65% | 111B | |
+11.23% | 106B | |
-12.33% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.60% | 16.81B | |
+38.60% | 12.54B | |
-24.25% | 8.09B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- HC Wainwright Starts Halozyme Therapeutics at Buy With $61 Price Target